IN2014CN03647A - - Google Patents
Info
- Publication number
- IN2014CN03647A IN2014CN03647A IN3647CHN2014A IN2014CN03647A IN 2014CN03647 A IN2014CN03647 A IN 2014CN03647A IN 3647CHN2014 A IN3647CHN2014 A IN 3647CHN2014A IN 2014CN03647 A IN2014CN03647 A IN 2014CN03647A
- Authority
- IN
- India
- Prior art keywords
- dysfunctions
- psychotic
- alpha
- provides methods
- subject suffering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549319P | 2011-10-20 | 2011-10-20 | |
| PCT/IB2012/055692 WO2013057687A2 (fr) | 2011-10-20 | 2012-10-18 | Biomarqueurs prédictifs de la sensibilité au traitement par l'activateur du récepteur de l'acétylcholine nicotinique alpha 7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN03647A true IN2014CN03647A (fr) | 2015-10-09 |
Family
ID=47297333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3647CHN2014 IN2014CN03647A (fr) | 2011-10-20 | 2012-10-18 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2768507B1 (fr) |
| JP (1) | JP6162705B2 (fr) |
| KR (1) | KR102043077B1 (fr) |
| CN (1) | CN103930112B (fr) |
| AU (1) | AU2012324458B2 (fr) |
| BR (1) | BR112014007485B1 (fr) |
| CA (2) | CA2852268C (fr) |
| EA (1) | EA034964B1 (fr) |
| ES (1) | ES2776996T3 (fr) |
| IN (1) | IN2014CN03647A (fr) |
| JO (1) | JO3766B1 (fr) |
| MX (1) | MX2014004621A (fr) |
| TW (1) | TWI635861B (fr) |
| WO (1) | WO2013057687A2 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 化学修飾ｍＲＮＡ |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| US9597284B2 (en) | 2014-10-20 | 2017-03-21 | Oyster Point Pharma, Inc. | Dry eye treatments |
| PT3439661T (pt) | 2016-04-07 | 2021-09-30 | Oyster Point Pharma Inc | Métodos de tratamento de condições oculares |
| WO2017201364A1 (fr) * | 2016-05-20 | 2017-11-23 | Vanda Pharmaceuticals Inc. | Procédé d'amélioration ou d'augmentation de la cognition |
| CN107188900B (zh) * | 2017-05-27 | 2019-09-06 | 北京师范大学 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
| JP2022538955A (ja) | 2019-03-19 | 2022-09-07 | ケンブリッジ コグニション リミテッド | 精神障害のための治療の診断および推奨の方法および利用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
| CA2153387A1 (fr) | 1993-01-07 | 1994-07-21 | Hubert Koester | Sequencage de l'adn par spectrometrie de masse |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| CA2403937A1 (fr) | 2000-04-05 | 2001-10-18 | Glaxo Group Limited | Analyse iterative de populations non-reactives dans la conception d'etudes pharmacogenetiques |
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
| DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
| GB0220581D0 (en) * | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| JP4890762B2 (ja) | 2002-09-25 | 2012-03-07 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール、ベンゾチアゾール、及びベンゾイソチアゾール、並びにそれらの調製及び使用 |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| EP1824848A1 (fr) | 2004-12-10 | 2007-08-29 | Abbott Laboratories | Derives polycycliques de quinuclidine substitues par un bicycloheterocycle condense |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| DK2018380T3 (da) | 2006-05-19 | 2012-01-23 | Abbott Lab | CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| WO2009066107A1 (fr) | 2007-11-21 | 2009-05-28 | Astrazeneca Ab | Utilisation d'un agoniste d'un récepteur nicotinique |
| ES2407647T3 (es) | 2008-10-13 | 2013-06-13 | F. Hoffmann-La Roche Ag | Método libre de diazonio para obtener un intermediario indazol en la síntesis de amidas de ácido bicíclico 5-(trifluorometoxi)-1H-3-indazol carboxílico |
| US20110262407A1 (en) | 2008-11-11 | 2011-10-27 | Targacept, Inc. | Treatment with alpha7 selective ligands |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| JO3250B1 (ar) * | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
-
2012
- 2012-10-18 JP JP2014536391A patent/JP6162705B2/ja active Active
- 2012-10-18 ES ES12797979T patent/ES2776996T3/es active Active
- 2012-10-18 BR BR112014007485-2A patent/BR112014007485B1/pt active IP Right Grant
- 2012-10-18 CA CA2852268A patent/CA2852268C/fr active Active
- 2012-10-18 KR KR1020147010115A patent/KR102043077B1/ko active IP Right Grant
- 2012-10-18 EP EP12797979.7A patent/EP2768507B1/fr active Active
- 2012-10-18 AU AU2012324458A patent/AU2012324458B2/en active Active
- 2012-10-18 WO PCT/IB2012/055692 patent/WO2013057687A2/fr active Application Filing
- 2012-10-18 MX MX2014004621A patent/MX2014004621A/es active IP Right Grant
- 2012-10-18 EA EA201490832A patent/EA034964B1/ru unknown
- 2012-10-18 JO JOP/2012/0311A patent/JO3766B1/ar active
- 2012-10-18 IN IN3647CHN2014 patent/IN2014CN03647A/en unknown
- 2012-10-18 CN CN201280051452.1A patent/CN103930112B/zh active Active
- 2012-10-18 CA CA3083244A patent/CA3083244C/fr active Active
- 2012-10-19 TW TW101138792A patent/TWI635861B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013057687A2 (fr) | 2013-04-25 |
| CA2852268A1 (fr) | 2013-04-25 |
| CA3083244A1 (fr) | 2013-04-25 |
| ES2776996T3 (es) | 2020-08-03 |
| CN103930112A (zh) | 2014-07-16 |
| AU2012324458B2 (en) | 2016-05-19 |
| TWI635861B (zh) | 2018-09-21 |
| CA3083244C (fr) | 2023-01-03 |
| CN103930112B (zh) | 2018-11-09 |
| AU2012324458A1 (en) | 2014-05-01 |
| KR20140081822A (ko) | 2014-07-01 |
| CA2852268C (fr) | 2020-08-25 |
| TW201322980A (zh) | 2013-06-16 |
| WO2013057687A3 (fr) | 2013-07-11 |
| JP2015501306A (ja) | 2015-01-15 |
| JO3766B1 (ar) | 2021-01-31 |
| JP6162705B2 (ja) | 2017-07-12 |
| KR102043077B1 (ko) | 2019-11-11 |
| EA201490832A1 (ru) | 2015-12-30 |
| EP2768507B1 (fr) | 2019-12-11 |
| EA034964B1 (ru) | 2020-04-13 |
| EP2768507A2 (fr) | 2014-08-27 |
| BR112014007485B1 (pt) | 2022-05-31 |
| BR112014007485A2 (pt) | 2017-04-04 |
| MX2014004621A (es) | 2014-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN03647A (fr) | ||
| JO3715B1 (ar) | منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني | |
| PH12014500995A1 (en) | Pak inhibitors for the treatment of cell proliferative disorders | |
| HK1254745A1 (zh) | Gpr119受體調節劑和對與其相關的障礙的治療 | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| JO3131B1 (ar) | مركبات كيميائية | |
| HK1199030A1 (zh) | 用於治療 受體相關疾病的取代的 -苯基吡啶 | |
| WO2012118750A3 (fr) | Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b | |
| EP2817068A4 (fr) | Compositions et méthodes destinées à traiter les troubles neurogènes du plancher pelvien | |
| TW200745109A (en) | Pyrrolo-pyridine kinase modulators | |
| IN2014DN00288A (fr) | ||
| IN2014DN00286A (fr) | ||
| IN2014MN00093A (fr) | ||
| MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
| WO2008124849A3 (fr) | Modulateurs de pyrrolo-pyridine kinase | |
| GB201103062D0 (en) | Method | |
| IN2012DN02485A (fr) | ||
| IN2014MN01378A (fr) | ||
| MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
| IL232334A0 (en) | Modulators of the G protein-coupled mas receptor and the treatment of related disorders | |
| EP2605655A4 (fr) | Méthodes de traitement de troubles cognitifs légers (mci) et de troubles associés | |
| EP3110974A4 (fr) | Méthodes d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central | |
| WO2012173846A3 (fr) | Macrocycles peptidomimétiques | |
| SG11201406192VA (en) | Method for assessing the treatment of attention-deficit/hyperactivity disorder | |
| MX360710B (es) | Antagonistas de il17c para el tratamiento de trastornos inflamatorios. |